News Releases

Date	Title and Summary	View
Jan 30, 2020	Janssen Announces European Commission Approval for Expanded Use of Erleada®▼ (apalutamide) for Treatment of Patients with Metastatic Hormone-Sensitive Prostate Cancer
Jan 29, 2020	Johnson & Johnson Launches Multi-Pronged Response to Coronavirus Global Public Health Threat Initiating Vaccine Development and Providing Supplies of Antiviral Medicines to China for Investigational Use NEW BRUNSWICK, N.J. , Jan. 29, 2020 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that it is mobilizing resources at its Janssen Pharmaceutical Companies to launch a
Jan 23, 2020	The European Commission Approves Expanded Use Of JANSSEN’S STELARA® (USTEKINUMAB) For The Treatment Of Paediatric Patients With Moderate To Severe Plaque Psoriasis
Jan 22, 2020	Johnson & Johnson Reports 2019 Fourth-Quarter And Full Year Results: - 2019 Fourth-Quarter Sales of $20.7 Billion reflecting growth of 1.7%, operational growth of 2.6%* and adjusted operational growth of 3.4%* - 2019 Full-Year Sales of $82.1 Billion reflecting growth of 0.6%, operational growth of 2.8%* and adjusted operational growth of 4.5%* - 2019 Fourth-Quarter
Jan 20, 2020	European Commission Approves Darzalex®▼ (daratumumab) in Combination with Bortezomib, Thalidomide and Dexamethasone (VTd) for Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible
Jan 20, 2020	Janssen Seeks Expanded Use of IMBRUVICA® (ibrutinib) in Combination with Rituximab for Patients with Previously Untreated Chronic Lymphocytic Leukaemia (CLL)
Jan 15, 2020	Janssen Seeks Expanded Use of SPRAVATO®▼ (Esketamine) Nasal Spray in Europe as a Treatment for Depressive Symptoms in Adults with Major Depressive Disorder Who Have Current Suicidal Ideation with Intent
Jan 02, 2020	Johnson & Johnson Announces Quarterly Dividend for First Quarter 2020 NEW BRUNSWICK, N.J., Jan. 2, 2020 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the first quarter of 2020 of $0.95 per share on the company's common stock. The dividend is payable on March 10, 2020 to shareholders of
Dec 30, 2019	Janssen Announces Completion of Acquisition of Investigational Bermekimab from XBiotech Inc. HORSHAM, Pa. , Dec. 30, 2019 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE: JNJ) announced today the completion of the acquisition of all rights to the investigational compound bermekimab, which has multiple dermatological indications, along with certain
Dec 21, 2019	Complete Response Letter Issued from U.S. FDA for Investigational Long-Acting HIV Regimen